Status: Recruiting
IV Iron-induced Hypophosphatemia After RYGB
The primary objective of the study is to compare the incidence of hypophosphatemia in RYGB patients treated with intravenous (IV) single dose of iron isomaltoside (Monofer®) or ferric carboxymaltose (Ferinject®).
Participants needed: 94
Trial details
Phase: Phase 4Age: 18-99Biological sex: AllType: InterventionalSponsor: Lucie FavreUpdated: Aug 20, 2024Locations: 1
Eligibility criteria
Patients over 18 years [+7]
- Patients with known hypersensitivity to iron preparation and/or anaphylaxis fr... [+15]